Siemens AG: Acquisition of Bayer Diagnostics – Medical Solutions Group further expands position in key high-growth molecular diagnostics market

Ad hoc announcement transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
---

Siemens has signed an agreement with Bayer to acquire the chemical and
pharmaceutical company’s Diagnostics Division. The acquisition will enable
Siemens Medical Solutions to expand its position in the high-growth
molecular diagnostics market. The purchase price for Bayer HealthCare
Diagnostics – which had sales of €1.4 billion and a double-digit EBITDA
margin in fiscal 2005 – is roughly €4.2 billion. This acquisition is
subject to regulatory approvals.
 
With the acquisition Bayer Diagnostics Siemens consequently executes on its
strategy in the area of Healthcare. For the first time in the healthcare
industry an integrated diagnostics is being created company by combining
the entire imaging diagnostics, laboratory diagnostics and clinical IT
value chain under one roof.

This acquisition would make Siemens Medical Solutions No. 2 worldwide in
immunodiagnostics. In addition, this will enable the Siemens Group to tap
the rapidly growing market for molecular diagnostics based on gene analysis
(nucleid acid testing). Bayer Diagnostics is also a world market-leader in
clinical chemistry with a leading position in near-patient testing,
laboratory automation and hematology (blood cell diagnostics).

---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

A Siemens press conference will be held in Munich on June 30, 2006, at
10:00 a.m. (CEST) on the acquisition of Bayer Diagnostics by Siemens
Medical Solutions. Dr. Klaus Kleinfeld, CEO of Siemens AG, and Dr. Erich
Reinhardt, Group President of Siemens Medical Solutions, will host the
conference. The telephone transmission (listen only) of this conference can
be heard at the dial-in numbers +49 (0)89 2030 3244 (in German) and +49
(0)89 2030 3242 (English) or on the Internet via audio streaming at:
www.siemens.com/presse. Please dial in at latest 15 minutes before the
press conference begins. A recording of the conference will be available on
the Internet immediately afterwards.

A telephone conference with Dr. Klaus Kleinfeld and Dr. Erich Reinhardt
will also be held for American journalists on June 30, 2006, at 3:00 p.m.
(CEST). This conference can be followed in ‘listen only’ mode by dialing in
+49 (0)69 2222 2246. Please dial in at latest 15 minutes before the press
conference begins.

A conference call for financial analysts and investors will take place on
June 30 at 12 noon (CEST). This conference call can be followed in the
Internet at: www.siemens.com/analystcall.
 
Siemens Medical Solutions develops products and services that improve
recovery rates by diagnosing diseases earlier and more accurately. Its goal
is to enable its customers to increase healthcare quality while improving
efficiency. Siemens is an innovations driver in diagnostic imaging systems
(in-vivo diagnostics) and the market leader in healthcare IT.

The company strengthened its position in molecular in-vivo diagnostics last
year through the acquisition of CTI, delivering increased capabilities in
the development and manufacture of positron emission tomography (PET)
systems that can be used, for example, in the diagnosis of cancer and
Alzheimer’s disease, in addition to advanced development of new molecular
contrast agents and pharmaceutical tracers.

At the end of April, Siemens announced the planned acquisition of
Diagnostic Products Corporation (DPC) in the U.S., a leading company in
immunodiagnostics.




(c)DGAP 29.06.2006 
---------------------------------------------------------------------------
 
Language:     English
Issuer:       Siemens Aktiengesellschaft
              Wittelsbacherplatz 2
              80333 München Deutschland
Phone:        +49 (0)89 636-00
Fax:          +49 (0)89  636-32908
E-mail:       investorrelations@siemens.com
WWW:          www.siemens.com
ISIN:         DE0007236101
WKN:          723610
Indices:      DAX, EURO STOXX 50
Listed:       Amtlicher Markt in Berlin-Bremen, Frankfurt (Prime Standard),
              Hannover, München, Hamburg, Düsseldorf, SWX, Stuttgart;
              Foreign Exchange(s) London, NYSE
 
End of News                                     DGAP News-Service
 
---------------------------------------------------------------------------